{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:02:01Z","timestamp":1792594921608,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.mcna.2025.02.017","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T19:18:42Z","timestamp":1744226322000},"page":"803-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation Therapy for Venous Thromboembolism"],"prefix":"10.1016","volume":"109","author":[{"given":"Phillip","family":"Anjum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kimbrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Akbashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"13","key":"10.1016\/j.mcna.2025.02.017_bib3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.2021.13844","article-title":"US emergency department visits attributed to medication harms, 2017-2019","volume":"326","author":"Budnitz","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib4","first-page":"868","article-title":"Estimated discounts generated by Medicare drug negotiation in 2026","volume":"29","author":"Hernandez","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.mcna.2025.02.017_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.amepre.2023.10.014","article-title":"Trends in drug spending of oral anticoagulants for atrial fibrillation, 2014\u20132021","volume":"66","author":"Lee","year":"2024","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/d41573-024-00041-3","article-title":"Top companies and drugs by sales in 2023","volume":"23","author":"Verdin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"10.1016\/j.mcna.2025.02.017_bib7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM196905292802202","article-title":"Resolution rate of acute pulmonary embolism in man","volume":"280","author":"Dalen","year":"1969","journal-title":"N Engl J Med"},{"issue":"23 Suppl 1","key":"10.1016\/j.mcna.2025.02.017_bib8","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"issue":"7810","key":"10.1016\/j.mcna.2025.02.017_bib9","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants\u2019 data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.mcna.2025.02.017_bib10","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cells11203214","article-title":"Anticoagulants: a short history, their mechanism of action, pharmacology, and indications","volume":"11","author":"Heestermans","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.mcna.2025.02.017_bib11","doi-asserted-by":"crossref","first-page":"e211693","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US medicare beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"5","key":"10.1016\/j.mcna.2025.02.017_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019002364","article-title":"Long-term treatment of venous thromboembolism","volume":"135","author":"Kearon","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mcna.2025.02.017_bib13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/acem.12711","article-title":"Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis","volume":"22","author":"Beam","year":"2015","journal-title":"Acad Emerg Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.02.017_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.02.017_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.mcna.2025.02.017_bib16","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib17","article-title":"Treatment of distal deep vein thrombosis","volume":"4","author":"Kirkilesis","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"7915","key":"10.1016\/j.mcna.2025.02.017_bib18","first-page":"1","article-title":"When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found","volume":"347","author":"Wiener","year":"2013","journal-title":"BMJ (Online)"},{"issue":"5","key":"10.1016\/j.mcna.2025.02.017_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jamcollsurg.2008.12.030","article-title":"Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli","volume":"208","author":"Auer","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.mcna.2025.02.017_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2214\/AJR.14.13938","article-title":"Overdiagnosis of pulmonary embolism by pulmonary CT angiography","volume":"205","author":"Hutchinson","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M21-2981","article-title":"Risk for recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation : a multicenter prospective cohort study","volume":"175","author":"Le Gal","year":"2022","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26898","article-title":"Prevalence of and eligibility for surveillance without anticoagulation among adults with lower-risk acute subsegmental pulmonary embolism","volume":"6","author":"Rouleau","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.mcna.2025.02.017_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040151","article-title":"Clinical surveillance vs. anticoagulation for low-risk patients with isolated subsegmental pulmonary embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)","volume":"10","author":"Baumgartner","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1008740","article-title":"Deep-vein thrombosis of the upper extremities","volume":"364","author":"Kucher","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1378\/chest.07-1432","article-title":"Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE registry","volume":"133","author":"Mu\u00f1oz","year":"2008","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.mcna.2025.02.017_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jth.15614","article-title":"Anticoagulant treatment for upper extremity deep vein thrombosis: a systematic review and meta-analysis","volume":"20","author":"Valeriani","year":"2022","journal-title":"J Thromb Haemostasis"},{"issue":"12","key":"10.1016\/j.mcna.2025.02.017_bib27","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/jth.13524","article-title":"The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study","volume":"14","author":"Kyrle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib29","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.amjmed.2015.04.009","article-title":"Phlegmasia cerulea dolens: a rare clinical presentation","volume":"128","author":"Onuoha","year":"2015","journal-title":"Am J Med"},{"issue":"9785","key":"10.1016\/j.mcna.2025.02.017_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial","volume":"378","author":"Aujesky","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2011.04388.x","article-title":"Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study","volume":"9","author":"Zondag","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mcna.2025.02.017_bib32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1378\/chest.120.3.791","article-title":"Clinical suspicion of fatal pulmonary embolism","volume":"120","author":"Pineda","year":"2001","journal-title":"Chest"},{"issue":"13","key":"10.1016\/j.mcna.2025.02.017_bib33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.107.726232","article-title":"Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry","volume":"117","author":"Laporte","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2025.02.017_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2023.10.003","article-title":"Anticoagulation in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis","volume":"231","author":"Ishisaka","year":"2023","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment","volume":"41","author":"Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.mcna.2025.02.017_bib37","unstructured":"Dalteparin Sodium Injection. Package insert. Pfizer Laboratories Division Pfizer Inc.; 2022."},{"key":"10.1016\/j.mcna.2025.02.017_bib38","unstructured":"Enoxaparin Sodium. Package Insert. Amphastar pharmaceuticals, Inc.; 2017."},{"issue":"2 SUPPL","key":"10.1016\/j.mcna.2025.02.017_bib39","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants - antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.mcna.2025.02.017_bib40","unstructured":"Warfarin Sodium. Package Insert. Camber Pharmaceuticals; 2012."},{"key":"10.1016\/j.mcna.2025.02.017_bib41","unstructured":"Apixaban. Package insert. Bristol Myers Squibb; 2021."},{"key":"10.1016\/j.mcna.2025.02.017_bib42","unstructured":"Rivaroxaban. Package Insert. Janssen Pharmaceuticals, Inc.; 2023."},{"key":"10.1016\/j.mcna.2025.02.017_bib43","unstructured":"Edoxaban. Package Insert. Daiichi Sankyo CO., LTD.; 2023."},{"key":"10.1016\/j.mcna.2025.02.017_bib44","unstructured":"Fondaparinux Sodium. Package Insert. Dr. Reddy\u2019s Laboratories Inc.; 2020."},{"key":"10.1016\/j.mcna.2025.02.017_bib45","unstructured":"Argatroban. Package Insert. Accord Healthcare Inc.; 2021."},{"key":"10.1016\/j.mcna.2025.02.017_bib46","unstructured":"Heparin Sodium. Package insert. Fresenius kabi USA, LLC; 2024; 2024."},{"issue":"2","key":"10.1016\/j.mcna.2025.02.017_bib47","article-title":"Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism","volume":"2","author":"Robertson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2025.02.017_bib48","unstructured":"Nadroparin. Package insert. Aspen Pharmacare Australia; 2017."},{"key":"10.1016\/j.mcna.2025.02.017_bib49","unstructured":"Tinzaparin Sodium. Package Insert. LEO Pharmaceutical Products; 2010."},{"issue":"22","key":"10.1016\/j.mcna.2025.02.017_bib50","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib51","first-page":"245","article-title":"Dosing of enoxaparin in renal impairment","volume":"42","author":"Shaikh","year":"2017","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib52","first-page":"821","article-title":"The complex clinical picture of side effects to anticoagulation","volume":"94","author":"Trautmann","year":"2010","journal-title":"Med Clin"},{"key":"10.1016\/j.mcna.2025.02.017_bib53","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jamainternmed.2014.2368","article-title":"Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials","volume":"174","author":"Stergiopoulos","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib54","first-page":"556","article-title":"Updated guidelines on outpatient anticoagulation","volume":"87","author":"Wigle","year":"2013","journal-title":"Am Fam Physician"},{"issue":"27","key":"10.1016\/j.mcna.2025.02.017_bib55","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis","volume":"307","author":"Hull","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.02.017_bib56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1503\/cmaj.080171","article-title":"Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis","volume":"179","author":"Oake","year":"2008","journal-title":"CMAJ Canadian Medical Association Journal"},{"issue":"12","key":"10.1016\/j.mcna.2025.02.017_bib57","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mcna.2025.02.017_bib58","unstructured":"Dabigatran. Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc.; 2023."},{"key":"10.1016\/j.mcna.2025.02.017_bib59","unstructured":"Bivalirudin. Package Insert. Dr. Reddy\u2019s Laboratories Limited; 2019."},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib60","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"ACOG Practice Bulletin No. 196: thromboembolism in pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.mcna.2025.02.017_bib61","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0735-1097(99)00044-3","article-title":"Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves","volume":"33","author":"Nicola","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib62","first-page":"651","article-title":"Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting","volume":"116","author":"Beyer-Westendorf","year":"2016","journal-title":"Thromb Haemost"},{"issue":"22","key":"10.1016\/j.mcna.2025.02.017_bib63","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.mcna.2025.02.017_bib64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40256-022-00524-x","article-title":"Apixaban use in obese patients: a review of the pharmacokinetic, interventional, and observational study data","volume":"22","author":"Jamieson","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib65","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemostasis"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib66","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1055\/s-0043-1776989","article-title":"Direct-acting oral anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications","volume":"8","author":"Talerico","year":"2024","journal-title":"TH Open"},{"issue":"6","key":"10.1016\/j.mcna.2025.02.017_bib67","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.mcna.2025.02.017_bib68","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","article-title":"The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)","volume":"3","author":"Barba","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5428\/pcar20130417","article-title":"One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events","volume":"19","author":"Chen","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.13024","article-title":"Use of non-vitamin K antagonist oral anticoagulants 2008-2016: a Danish nationwide cohort study","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.mcna.2025.02.017_bib71","first-page":"1219","article-title":"Trajectories of adherence to extended treatment with direct oral anticoagulants and risks of recurrent venous thromboembolism and major bleeding","volume":"29","author":"Kang","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.mcna.2025.02.017_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2021.11.003","article-title":"Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: findings from the switching study","volume":"208","author":"Bartoli-Abdou","year":"2021","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.mcna.2025.02.017_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-019-01959-x","article-title":"Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center","volume":"49","author":"Patel","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"9383","key":"10.1016\/j.mcna.2025.02.017_bib75","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)14111-6","article-title":"Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study","volume":"362","author":"Baglin","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010301","article-title":"Choice and duration of anticoagulation for venous thromboembolism","volume":"13","author":"Malik","year":"2024","journal-title":"J Clin Med"},{"issue":"23_suppl_1","key":"10.1016\/j.mcna.2025.02.017_bib77","doi-asserted-by":"crossref","first-page":"I-9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"issue":"9889","key":"10.1016\/j.mcna.2025.02.017_bib78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(13)60592-9","article-title":"Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis","volume":"382","author":"Chopra","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mcna.2025.02.017_bib79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2019.10.058","article-title":"Incident heart failure and long-term risk for venous thromboembolism","volume":"75","author":"Fanola","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mcna.2025.02.017_bib80","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1183\/09031936.00043313","article-title":"Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib81","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"12","author":"Christiansen","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. a systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.mcna.2025.02.017_bib83","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1538-7836.2012.04735.x","article-title":"Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)","volume":"10","author":"Tosetto","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1016\/j.mcna.2025.02.017_bib84","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mcna.2025.02.017_bib85","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib86","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.jtha.2024.05.031","article-title":"Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study","volume":"22","author":"Guman","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.mcna.2025.02.017_bib87","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1055\/s-0041-1729171","article-title":"Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores","volume":"5","author":"Lecumberri","year":"2021","journal-title":"TH Open"},{"issue":"21","key":"10.1016\/j.mcna.2025.02.017_bib88","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.mcna.2025.02.017_bib89","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2025.02.017_bib90","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.02.017_bib91","doi-asserted-by":"crossref","first-page":"949","DOI":"10.7326\/M22-3559","article-title":"Indefinite anticoagulant therapy for first unprovoked venous thromboembolism","volume":"176","author":"Khan","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib92","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12875-021-01590-x","article-title":"Patients\u2019 and clinicians\u2019 perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis","volume":"22","author":"Osasu","year":"2021","journal-title":"BMC Fam Pract"},{"issue":"16","key":"10.1016\/j.mcna.2025.02.017_bib93","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or pci in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2025.02.017_bib94","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mcna.2025.02.017_bib95","first-page":"690","article-title":"Aspirin deprescribing in patients on oral anticoagulation for atrial fibrillation or venous thromboembolism: a national survey of clinician practices","volume":"6","author":"Ou","year":"2023","journal-title":"J Bone Joint Surg Am"},{"issue":"12","key":"10.1016\/j.mcna.2025.02.017_bib96","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mcna.2025.02.017_bib97","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1212\/WNL.0000000000207422","article-title":"Association of alternative anticoagulation strategies and outcomes in patients with ischemic stroke while taking a direct oral anticoagulant","volume":"101","author":"Ip","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2025.02.017_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-024-00352-x","article-title":"Factor XI inhibitors: a new horizon in anticoagulation therapy","volume":"13","author":"Presume","year":"2024","journal-title":"Cardiol Ther"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:11:31Z","timestamp":1749503491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0025712525000379"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.02.017","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation Therapy for Venous Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}